BINEX Co., Ltd. (KOSDAQ:053030)
South Korea · Delayed Price · Currency is KRW 14,280
-820 (-5.43%)
At close: Feb 6, 2026
BINEX Revenue
BINEX had revenue of 45.36B KRW in the quarter ending September 30, 2025, with 37.84% growth. This brings the company's revenue in the last twelve months to 165.64B, up 27.79% year-over-year. In the year 2024, BINEX had annual revenue of 130.05B, down -16.00%.
Revenue (ttm)
165.64B
Revenue Growth
+27.79%
P/S Ratio
2.75
Revenue / Employee
254.82M
Employees
650
Market Cap
454.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.05B | -24.77B | -16.00% |
| Dec 31, 2023 | 154.82B | -1.85B | -1.18% |
| Dec 31, 2022 | 156.68B | 22.28B | 16.58% |
| Dec 31, 2021 | 134.40B | 1.42B | 1.07% |
| Dec 31, 2020 | 132.98B | 7.72B | 6.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.40T |
| Bioneer | 320.69B |
| JETEMA, | 75.55B |
| Onconic Therapeutics | 46.65B |
| Pharmicell | 23.94B |
| SillaJen | 7.84B |
| Anterogen.Co.,Ltd. | 7.32B |
| Genomictree | 3.76B |